Previous 10 | Next 10 |
Inovio Pharmaceuticals (NASDAQ: INO) and Vaxart (NASDAQ: VXRT) are both small biotech companies that have made names for themselves by initiating coronavirus vaccine projects. So far, both have made some progress, and early clinical trials proceeded largely as planned. Their...
Sorrento currently presents a wide multitude of candidate drugs to combat COVID-19. Due to this huge Covid-19 program, the share price has skyrocketed in recent months, although since the August peak the stock price has been deflating to reach around $7. The problem here is that t...
At the start of the year, Vaxart (NASDAQ: VXRT) was a biotech company with a market cap of about $17 million and a stock price of less than $1. Once the company entered the coronavirus vaccine race, however, its fortunes -- and those of its investors -- changed. The stock climbed as...
SAN FRANCISCO, CA / ACCESSWIRE / October 23, 2020 / Hagens Berman alerts Vaxart, Inc. (NASDAQ:VXRT) investors of today's deadline to move for lead plaintiff in a securities fraud class action pending against the Company and urges VXRT investors who have suffered losses to contact the fi...
Vaxart, an oral tablet vaccine developer, has initiated and dosed the first participants in their phase 1 trial for COVID-19. Although later in development, Vaxart's oral tablet vaccine presents significant advantages in manufacture, distribution and ease-of- administration that may c...
Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Vaxart To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - October 20, 2020) - If you suffered losses exceeding $50,000 investing in Vaxart stock or opt...
Are These The Best Pharmaceutical Stocks To Buy Now? Pharmaceutical stocks have been sizzling hot this year. The defensive nature has gotten a boost, propelled by expectations for a vaccine and other therapies to treat the novel coronavirus. Pharmaceutical giant Pfizer ( PFE S...
Vaxart (NASDAQ: VXRT) , a clinical-stage vaccine developer, is poised for a tough day today. Ahead of the opening bell, the biotech's shares dropped by as much as 9.9%. The culprit? Vaxart's stock is sinking this morning in response to an 8-K filed with the Securities and Exchan...
Vaxart (VXRT) is down 6% premarket on increased volume. Shares have sold off over 20% since last week after it disclosed a $250M at-the-market stock sales deal with Jefferies.Shares are down 65% since touching $17.49 on July 14. A Phase 1 study evaluating its ora...
The9 (NCTY) -18%.Emerson Radio (MSN) -12%.American Equity Investment Life (AEL) -9% as Citi raises Brookfield Asset Management as AEL deal opens growth plan.ReWalk Robotics (RWLK) -10% on appointment of Randel Richner to the Board of Directors, effective November...
News, Short Squeeze, Breakout and More Instantly...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per ...